Product Overview

Onglyza 5 mg is a prescription anti‑diabetic medication that contains the active ingredient saxagliptin. It is manufactured by AstraZeneca Pharma India Ltd and is supplied as film‑coated tablets for the management of type 2 diabetes mellitus. Each strip contains 14 tablets, and the product is packaged in three convenient strengths: 28, 56, and 84 tablets per box, allowing patients to select the pack size that best fits their treatment plan. Onglyza belongs to the dipeptidyl peptidase‑4 (DPP‑4) inhibitor class, which enhances the body’s incretin hormone activity to improve glycemic control. The medication is indicated as an adjunct to diet and exercise for patients with type 2 diabetes who require additional pharmacologic therapy.

What is Onglyza (Saxagliptin)

Onglyza is the branded name for saxagliptin, a highly selective inhibitor of the enzyme DPP‑4. By blocking DPP‑4, the drug prolongs the lifespan of incretin hormones such as GLP‑1 and GIP, which are released from the gastrointestinal tract in response to food intake. These hormones stimulate insulin secretion from pancreatic β‑cells in a glucose‑dependent manner and suppress glucagon release when blood glucose levels rise. This dual action results in lower fasting and post‑prandial glucose concentrations without causing excessive hypoglycemia. The medication is taken orally once daily, regardless of meals, and is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

Uses and Benefits

Onglyza is prescribed to improve glycemic control in adults with type 2 diabetes mellitus. When used as monotherapy, it typically reduces glycated hemoglobin (HbA1c) by 0.5% to 0.8% compared with placebo. When combined with other oral antidiabetic agents such as metformin or sulfonylureas, additional HbA1c reductions of approximately 0.5% can be achieved. Key benefits include:

• Once‑daily dosing that supports adherence.
• Low risk of hypoglycemia when used alone or with metformin.
• Weight‑neutral profile, which is advantageous for patients concerned about weight gain.
• No requirement for dose adjustment based on food intake.

Long‑term studies have also suggested cardiovascular safety, making Onglyza a suitable option for patients with existing cardiovascular disease or multiple cardiovascular risk factors.

How It Works

The pharmacologic mechanism of saxagliptin centers on the inhibition of DPP‑4, an enzyme that rapidly degrades incretin hormones. By preventing this degradation, saxagliptin increases the circulating concentrations of GLP‑1 and GIP, leading to enhanced insulin secretion from pancreatic β‑cells when glucose levels are elevated. Simultaneously, glucagon release is suppressed during hyperglycemia, reducing hepatic glucose production. This glucose‑dependent action minimizes the likelihood of hypoglycemia, a common concern with many antidiabetic agents. The drug’s half‑life is approximately 23 hours, supporting its once‑daily administration.

Dosage Guidelines

The recommended starting dose of Onglyza is 5 mg taken once daily. For patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m²), the dose may be reduced to 2.5 mg once daily to avoid accumulation. No dose adjustment is necessary for mild renal impairment (eGFR ≥60 mL/min/1.73 m²). In patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), Onglyza is not recommended. Hepatic function does not require dose modification, but caution is advised in individuals with severe liver disease. The tablet should be swallowed whole with water; it may be taken with or without food. Consistent daily dosing is essential to maintain therapeutic efficacy.

Side Effects

Adverse reactions associated with Onglyza are generally mild to moderate. The most frequently reported side effects include nasopharyngitis, urinary tract infections, and headache. Less common but clinically important adverse events comprise:

• Acute pancreatitis – characterized by persistent abdominal pain, nausea, and vomiting.
• Severe joint pain or arthralgia.
• Hypersensitivity reactions such as skin rash, pruritus, or angioedema.

Patients should discontinue the medication and seek immediate medical attention if they experience symptoms suggestive of pancreatitis or an allergic reaction. Reporting of side effects to a healthcare professional is recommended.

Warnings and Precautions

Before initiating therapy, clinicians should assess renal function, as dose reduction is required for patients with eGFR 30–59 mL/min/1.73 m². Onglyza is contraindicated in patients with an eGFR <30 mL/min/1.73 m². Caution is advised in individuals with a history of pancreatitis, severe heart failure, or prior hypersensitivity to saxagliptin. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) may increase saxagliptin exposure and should be avoided unless the benefits outweigh the risks. Pregnant or lactating women should only use Onglyza if the potential maternal benefit justifies the potential risk to the fetus or infant, and they should consult a physician before use.

Drug Interactions

Onglyza is primarily metabolized by cytochrome P450 enzymes CYP3A4 and CYP2C8. Co‑administration with potent inhibitors of these enzymes can increase saxagliptin plasma concentrations, while inducers may decrease exposure. Notable interactions include:

• Strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin.
• Strong CYP3A4 inducers: rifampin, carbamazepine, phenytoin.
• Drugs that affect renal function (e.g., NSAIDs) may indirectly influence dosing considerations.

Healthcare providers should review a patient’s medication list for potential interactions and adjust dosing accordingly.

Storage and Handling

Onglyza tablets should be stored at room temperature (15°C–30°C) in the original packaging to protect them from moisture and light. The medication must be kept out of reach of children and pets. Do not use expired tablets. If a dose is missed, the patient should take it as soon as remembered unless it is close to the time for the next scheduled dose; in that case, the missed dose should be skipped and the regular schedule resumed.

Patient Counseling Points

Patients should be instructed to take Onglyza exactly as prescribed, without altering the dose or frequency. They should be reminded that the medication is only one component of a comprehensive diabetes management plan that includes dietary modifications, regular physical activity, and routine blood glucose monitoring. Education about the signs of hypoglycemia, pancreatitis, and allergic reactions is essential. Patients should also be advised to inform their healthcare provider of any new medications, supplements, or changes in health status.

Regulatory and Clinical Information

Onglyza received regulatory approval from the U.S. Food and Drug Administration (FDA) in 2009 for the treatment of type 2 diabetes. The FDA’s prescribing information can be accessed through the Drugs.com label repository (Onglyza FDA Label). Additional clinical data are available from peer‑reviewed studies indexed in PubMed and the National Institutes of Health (NIH) database (PubMed – Saxagliptin). The medication is listed on MedlinePlus, a service of the U.S. National Library of Medicine, for consumer education (MedlinePlus – Type 2 Diabetes).

Frequently Asked Questions

Can Onglyza be used with insulin therapy?

Yes, Onglyza can be used in combination with insulin, but dose adjustments of insulin may be necessary to reduce the risk of hypoglycemia. Close monitoring of blood glucose levels is recommended when these agents are co‑administered.

How long does it take to see a reduction in HbA1c?

Clinical trials have demonstrated that meaningful reductions in HbA1c are typically observed after 12 weeks of continuous therapy, with further improvements possible over longer treatment periods.

Is Onglyza associated with weight gain?

Onglyza is generally weight‑neutral; it does not typically cause significant weight gain or loss, making it a suitable option for patients who are concerned about weight management.

What should I do if I miss a dose?

If a dose is missed, the patient should take it as soon as remembered, provided it is not close to the time for the next scheduled dose. In such cases, the missed dose should be skipped, and the regular dosing schedule resumed.

Are there any dietary restrictions while taking Onglyza?

There are no specific dietary restrictions associated with Onglyza. However, maintaining a balanced diet and regular physical activity are essential components of diabetes management and can enhance the medication’s efficacy.

Related Products

• Esomeprazole 40 mg (Generic)
• Esomeprazole 20mg (Generic)
• Neksium (Esomeprazole)
• Neksium 20mg (Esomeprazole)
• Neksium 40 mg (Esomeprazole)
• Okamet 500 Mg (Metformin)
• Imdur (Isosorbide Mononitrate)
• Imdur 30 mg (Isosorbide Mononitrate)
• Imdur 60 mg (Isosorbide Mononitrate)
• Isosorbide Mononitrate Prolonged Release 60 mg (Generic)
• Isosorbide Mononitrate Prolonged Release 30 mg (Generic)
• Ticagrelor (Generic)